|
101 |
Evaluating the impact of the single exit price policy on a basket of originator medicines in South Africa from 1999 to 2014 using a time series analysis
Enthalten in BMC health services research Bd. 19, 16.8.2019, Nr. 1, date:12.2019: 1-13
|
|
|
|
102 |
Evaluation of adverse events focusing on infection associated with infliximab originator and biosimilar using a spontaneous reporting system database
Enthalten in Journal of pharmaceutical health care and sciences Bd. 5, 7.10.2019, Nr. 1, date:12.2019: 1-4
|
|
|
|
103 |
Forced Degradation Products of Liraglutide: A Comparative Study of Similarity Between Originator and Analogue Version by Liquid Chromatography–Mass Spectrometry
Enthalten in International journal of peptide research and therapeutics Bd. 30, 24.4.2024, Nr. 3, date:5.2024: 1-13
|
|
|
|
104 |
Forty-Eight-Month Monitoring of Disease Activity in Patients with Long-Standing Rheumatoid Arthritis Treated with TNF-α Inhibitors: Time for Clinical Outcome Prediction and Biosimilar vs Biologic Originator Performance
Enthalten in Clinical drug investigation Bd. 44, 31.1.2024, Nr. 3, date:3.2024: 141-148
|
|
|
|
105 |
Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Aspart (MYL-1601D) Compared with Originator Insulin Aspart (Novolog®) in Patients with Type 1 Diabetes After 24 Weeks: A Randomized Open-Label Study
Enthalten in BioDrugs Bd. 36, 17.9.2022, Nr. 6, date:11.2022: 761-772
|
|
|
|
106 |
Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis
Enthalten in BioDrugs Bd. 37, 23.3.2023, Nr. 3, date:5.2023: 409-420
|
|
|
|
107 |
Impact of switching from the originator adalimumab to a biosimilar: a retrospective cohort study
Enthalten in BMC immunology Bd. 26, 3.7.2025, Nr. 1, date:12.2025: 1-13
|
|
|
|
108 |
In Vitro Biological Characterization of Recombinant Insulin Aspart from Biogenomics and Originator Insulin Aspart
Enthalten in BioDrugs Bd. 37, 7.6.2023, Nr. 5, date:9.2023: 709-719
|
|
|
|
109 |
Incidence of and Reasons and Determinants Associated with Retransitioning from Biosimilar Etanercept to Originator Etanercept
Enthalten in BioDrugs Bd. 35, 26.10.2021, Nr. 6, date:11.2021: 765-772
|
|
|
|
110 |
Interchangeability and adverse events in originator-rituximab and its biosimilar (CT-P10) among rheumatic patients: a real-life experience
Enthalten in Internal and emergency medicine Bd. 18, 24.2.2023, Nr. 3, date:4.2023: 791-799
|
|
Administration
